The American College of Cardiology has made a major update to its recommendation for prevention of cardiovascular disease here:
https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024
In summary, they recommend that weight-loss drugs be used earlier to prevent heart disease, making them part of the first line of defense for obese patients. Previously, the first line of defense only included lifestyle modification. They also talk about the 2 options on the market today, and how they compare.
This looks like a major policy change, and will put more pressure on private and public insurance companies for broader support of GLP1 medication.